Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 145.24M | $ 146.03M | $ 157.07M | $ 209.82M | $ 108.08M |
| Gross Profit | $ 139.23M | $ 141.09M | $ 151.86M | $ 206.42M | $ 105.38M |
| Operating Income | $ -119.44M | $ -129.54M | $ -142.20M | $ -98.27M | $ -171.85M |
| EBITDA | $ -38.60M | $ -118.42M | $ -139.31M | $ -96.98M | $ -167.85M |
| Net Income | $ -76.42M | $ -143.10M | $ -165.29M | $ -124.09M | $ -196.27M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 108.71M | $ 191.44M | $ 277.97M | $ 228.62M | $ 249.24M |
| Total Assets | $ 164.42M | $ 240.44M | $ 358.17M | $ 305.31M | $ 313.05M |
| Total Debt | $ 194.52M | $ 177.02M | $ 179.07M | $ 180.58M | $ 131.13M |
| Net Debt | $ 132.05M | $ 124.78M | $ 43.89M | $ -9.88M | $ 45.21M |
| Total Liabilities | $ 350.44M | $ 376.64M | $ 374.83M | $ 384.98M | $ 262.50M |
| Stockholders' Equity | $ -186.02M | $ -136.21M | $ -16.66M | $ -79.67M | $ 50.55M |
| Cash Flow | |||||
| Free Cash Flow | $ -127.63M | $ -92.72M | $ -149.67M | $ -112.83M | $ -160.38M |
| Operating Cash Flow | $ -127.49M | $ -92.72M | $ -149.55M | $ -107.12M | $ -160.23M |
| Investing Cash Flow | $ 95.47M | $ 7.94M | $ -104.26M | $ 141.84M | $ -53.69M |
| Financing Cash Flow | $ 41.65M | $ 1.12M | $ 193.74M | $ 73.65M | $ 172.08M |